Sarah Travers

Travere Therapeutics Joins American Kidney Fund’s 2023 Corporate Membership Program at ‘Champion’ Level

Retrieved on: 
Friday, September 8, 2023
American Kidney Fund, Patient advocacy, AKF, Sarah Travers, Research, Patient, Risk, Kidney, Health, Therapy, Kidney disease, Disease, Pharmaceutical industry

ROCKVILLE, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Travere Therapeutics has joined the 2023 class in AKF’s Corporate Membership Program as a Champion-level member.

Key Points: 
  • ROCKVILLE, Md., Sept. 08, 2023 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Travere Therapeutics has joined the 2023 class in AKF’s Corporate Membership Program as a Champion-level member.
  • Travere’s membership will help fund AKF’s work to advance kidney disease awareness, prevention, early detection, treatment and research.
  • Recently, Travere supported AKF’s Unknown Causes of Kidney Disease Project , which aims to improve understanding of how undiagnosed or misdiagnosed causes of kidney disease directly impact patient care and outcomes.
  • The Corporate Membership Program is open to institutional partners that support AKF’s mission of fighting kidney disease and helping people live healthier lives.

Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023

Retrieved on: 
Thursday, June 8, 2023
Abstract, Era, Kidney failure, Heart Protection Study, Urine, Impact, Sarah Travers, Session, FSGS, Immunoglobulin A, ERA, Proteinuria, Congress, Art, Natural history, SAN, Kidney, Patient, Therapy, Death, PROTECT, Pharmaceutical industry, IgA nephropathy

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim analysis from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) versus an active comparator in IgA nephropathy (IgAN), at the 60th ERA Congress in Milan, Italy, June 15-18, 2023.

Key Points: 
  • SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present nine abstracts, including the interim analysis from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (sparsentan) versus an active comparator in IgA nephropathy (IgAN), at the 60th ERA Congress in Milan, Italy, June 15-18, 2023.
  • Also included in the presentations is a new analysis of the UK RaDaR Registry estimating the delay in time to kidney failure or death based on proteinuria reduction in IgAN, which has been designated among the 10 best-ranked abstracts of 2023 by ERA.
  • “We’re pleased to bring to the ERA Congress the strong interim results from our ongoing PROTECT Study which demonstrate that sparsentan significantly reduces proteinuria in IgA nephropathy,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics.
  • “We also look forward to sharing more data from the IgA nephropathy field showing the relationship between reducing proteinuria in IgA nephropathy and preservation of kidney function.”
    Session: The Art of Staring at Urine: Studies in IgA Nephropathy
    Session: The Art of Staring at Urine: Studies in IgA Nephropathy
    Alport Syndrome Natural History from the RaDaR Registry: Associations with Gene, Variant Type and Sex
    Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of IgAN and FSGS on Patients & Care-Partners Study (HONUS): US IgAN Results Update

Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

Retrieved on: 
Tuesday, November 15, 2022
SAN, Kidney disease, Life, Therapy, Social media, Caregiver, Patient, Education, Kidney, Sarah Travers, Immunoglobulin A, Chronic kidney disease, Parenting, Disease, Nephrotic syndrome, Parent, Letter, FSGS, CKD, Research, Hope, RKD, Pharmaceutical industry, Telescopic sight, Medicine, IgA nephropathy

Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease.

Key Points: 
  • Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease.
  • Due to low public awareness, people living with rare kidney disease can face challenges in getting diagnosed and finding support.
  • Rare kidney disease often presents with unique symptoms or no symptoms and can progress to end-stage kidney disease much faster than other forms of kidney disease, said Kelly Helm, executive director of patient engagement at NephCure Kidney International.
  • Anyone with an authentic connection to rare kidney disease is encouraged to submit a letter on RKDandMe.com to support raising awareness of RKD.